Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 1.00 |
| ▸ | SRC | P12931 | 8/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 7/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | RGS12 | O14924 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | GMNN | O75496 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | YES1 | P07947 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14519097 | 1.00 | KDR (1.00) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL2196602 | 1.00 | KDR (1.00) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL14519101 | 0.86 | PDGFRB (0.75) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL15202711 | 0.86 | PDGFRB (0.75) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL14519102 | 0.86 | PDGFRB (0.75) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL1062998 | 0.85 | KDR (1.00) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL14519098 | 0.85 | KDR (1.00) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL1063000 | 0.85 | KDR (1.00) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL12335930 | 0.83 | KDR (0.71) | KDRPDGFRBSRCFGFR1RET | |
| SCHEMBL3487517 | 0.83 | KDR (0.85) | KDRPDGFRBSRCFGFR1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | claimed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | claimed |
| EP-2114403-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | Bayer Healthcare, LLC (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008089388-A2 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2008-07-24 | — | — | WO | claimed |
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2017-06-22 | — | — | US | disclosed |
| US-9439961-B2 | Pharmaceutical composition for treating ischemic events | NIIGATA UNIVERSITY (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20140127233-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC EVENTS | NIIGATA UNIVERSITY (JP) | 2014-05-08 | — | — | US | disclosed |
| US-8652476-B2 | Pharmaceutical composition for treating ischemic events | NIIGATA UNIVERSITY (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| US-20120189631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ISCHEMIC EVENTS | NIIGATA UNIVERSITY (JP) | 2012-07-26 | — | — | US | disclosed |
| WO-2011081971-A2 | EGFR/VEGFR DUAL MODULATORS AND METHODS OF USING | CORNING INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER HEALTHCARE LLC (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2007059155-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20060241067-A1 | Methods For inhibiting angiogenesis, cell migration, cell adhesion, and cell survival | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-26 | — | — | US | disclosed |
| WO-2004001384-A2 | METHODS FOR INHIBITING ANGIOGENESIS, CELL MIGRATION, CELL ADHESION, AND CELL SURVIVAL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172989-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | KDR 2076/4885PDGFRB 2508/4885SRC 428/4885 |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | KDR 3/4885PDGFRB 13/4885SRC 37/4885 |
| US-20100173954-A1 | TREATMENT OF CANCERS HAVING RESISTANCE TO CHEMOTHERAPEUTIC AGENTS | CDK4, TP53, ABCC1 | KDR 2076/4885PDGFRB 2508/4885SRC 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.